Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Investor Presentation (June 2025)
41 slides from Indivior Pharmaceuticals's investor presentation, Jun 2, 2025
Slide 1: Investor Presentation June 2025
Exhibit 99.1 Investor Presentation June 2025 For Investor Relations Purposes Only
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding expec
Slide 3: Founded to Help Address the Opioid Crisis
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Founded to Help Address the Opioid Crisis Leading with Science Financial Strength • Leading in discovery and commercialization of buprenorphine evidence-based • $1,188m total net revenue (NR) (FY2024) medicines for opioid dependence for over
Slide 4: Track Record of Strong Net Revenue Growth
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Track Record of Strong Net Revenue Growth Revenue Growth Driven by the U.S.… …And Increasing Contribution from SUBLOCADE $1,188m $1,188m $1,093m $1,093m $901m $901m $1,008m $912m $791m $791m $647m $647m $756m $732m $630m $603m $456m $408m $24
Slide 5: Clear Path to Generating Meaningful Cash Flows from Operations
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Clear Path to Generating Meaningful Cash Flows from Operations Leverage Cost Structure… … To Drive Robust Bottom-line Growth $679m $651m $533m $320m $477m $462m 2 $274m $220m $188m 71% 27% 60% 25% 59% 59% 57% 24% 24% $88m 14% 2020 2021 2022 2
Slide 6: U.S. Commercial Portfolio Spanning Recovery and Rescue
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 U.S. Commercial Portfolio Spanning Recovery and Rescue Recovery Medicines Rescue Medicine Durable Growth Driver with Genericized Market Strong Patent Protection Strong Patent Protection 12 Orange Book patents 2 Orange Book patents Genericized
Slide 7: 2025: A Transition Year
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 2025: A Transition Year Current U.S. Dynamics Foundational Leadership Additions 2025 U.S. NR Headwinds: Strengthening expertise and leadership with Board of • SUBLOCADE NR impacted by funding gaps in the Criminal Justice Directors (BOD) and E
Slide 8: Transition Year Focus
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Transition Year Focus Deliver 2025 Operating Plan Grow SUBLOCADE Advance the OUD Pipeline Strengthen the Balance Sheet 7
Slide 9: SUBLOCADE
‘ =| INDIVIOR SUBLOCADE”
Slide 10: Bipartisan Commitment to Addressing Opioid Crisis in the U.S.
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Bipartisan Commitment to Addressing Opioid Crisis in the U.S. Opioid Overdoses U.S. Illicit Opioid Use Could AGED c c Remain the Leading Be 20 Times Higher Than May 12, 2025 18-44 Cause of Death Previously Estimated May 14, 2025 WTAS: Widespr
Slide 11: LAI Buprenorphine Medications are Under-Penetrated in the Treatment of OUD
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 LAI Buprenorphine Medications are Under-Penetrated in the Treatment of OUD Current 7% LAI usage in BMAT population allows for significant potential expansion 1 8.9m Misuse opioids in U.S. (Total Addressable Market) 1 5.9m OUD diagnosed in U.S
Slide 12: ASAM BMAT Guidelines
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 American Society of Addiction Medicine (ASAM) BMAT Guidelines 1 1,2 ASAM Clinical Guideline ASAM Clinical Consideration 1 Treatment Goals with Buprenorphine For Individuals using High-Potency Synthetic Opioids (HPSO) Suppress opioid Stop or R
Slide 13: ≥2 ng/mL Buprenorphine Plasma Levels Needed to Protect Most Patients
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 ≥2 ng/mL Buprenorphine Blood Plasma Levels are Needed to Help 1,2 Protect Most Patients from Opioid-Rewarding Effects As buprenorphine plasma levels increase, the number of receptors available for opioids decreases, 1,3,4 resulting in a decre
Slide 14: SUBLOCADE Delivers Continuous, Long-Lasting Protection All Month
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 SUBLOCADE Delivers Continuous, Long-Lasting Protection All Month with 1,2,3 a 43 to 60 Day Half-Life Mean Buprenorphine Levels During TM* BUP Induction, 5,6 Mean Weekly Buprenorphine Concentrations 4 Dose-Stabilization, and After the First 2
Slide 15: Longer SUBLOCADE Treatment Shown to Improve Patient Outcomes
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Longer SUBLOCADE Treatment Shown to Improve Patient Outcomes Continuous 12-month self-reported abstinence 75% if subjects stayed on SUBLOCADE for 12 months 80% 70% 75.0% The longer the SUBLOCADE 60% treatment duration, 50% the higher the like
Slide 16: SUBLOCADE Helps Transform Recovery
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 SUBLOCADE Helps Transform Recovery SUBLOCADE Offers Month Long Continuous Protection from Opioid-Rewarding Effects Continuous Protection Long-Lasting Reliable From the Start Effects Dosing ● Effective blockade from day 1 – the ● Longest half-
Slide 17: New SUBLOCADE Label Benefits
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 New SUBLOCADE Label Benefits Label Updates Further Differentiate SUBLOCADE for Today’s Opioid Crisis Driven by the Proliferation of Synthetic Opioids START PATIENTS ON SUBLOCADE SOONER: Only monthly CLINICALLY RELEVANT: Rapid initiation studi
Slide 18: Strong Fundamentals Position SUBLOCADE for Growth
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Strong Fundamentals Position SUBLOCADE for Growth 1 10,665 Growing SUBLOCADE Prescriber Base Prescribing Depth Improving: 5,277 1 HCPs with 5+ SUBLOCADE Patients 8,768 4,358 6,322 3,047 4,475 1,870 3,255 1,186 2020 2021 2022 2023 2024 2020 20
Slide 19: SUBLOCADE U.S. Commercial Focus
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 SUBLOCADE U.S. Commercial Focus GOAL: GOAL: SUBLOCADE as #1 LAI Choice LAI First Line in All Care Settings Enhanced competitiveness across all key channels Activate patients through direct-to-consumer (DTC) campaign Driving broad, rapid HCP a
Slide 20: OPVEE
{3s ys INDIVIOR
Slide 21: Potent Synthetic Opioids (Fentanyl) are Driving U.S. Overdose Crisis
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Potent Synthetic Opioids (Fentanyl) are Driving U.S. Overdose Crisis Contribution of Synthetic Opioids to ~26m People in the U.S. are All Opioid Overdose Deaths Potentially Misusing Synthetic Opioids 1 Illicit Fentanyl Use in the U.S. 0.9 (%
Slide 22: OPVEE Provides Rapid, Potent, Long-Lasting Reduction of Respiratory Depression
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 OPVEE Provides Rapid, Potent, Long-Lasting Reduction of Respiratory 1 Depression to Address the Current Wave of Synthetic Opioid Overdoses Triple Threat of Synthetic Opioid Rapid Potent Long-Lasting Pharmacology such as Fentanyl 2 BARDA Contr
Slide 23: Scientific Evidence Confirms OPVEE's Potential to Reverse Opioid Overdose
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Scientific Evidence Confirms OPVEE’s Potential to Improve and Sustain Reversal of an Opioid Overdose (5) OPVEE vs. 4mg nasal naloxone OPVEE compared with 4mg nasal naloxone OPNT0003 (3mg) Naloxone (4mg) (1) (1) Affinity at μ opioid receptors
Slide 24: Pipeline
Ee INDIVIOR
Slide 25: OUD Focused Pipeline
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 OUD Focused Pipeline Trial Patients & Population Design Primary Endpoints Estimated Completion INDV-6001 Evaluate PK, safety and 122 Patients 3-month long-acting Multiple dose tolerability of INDV-6001 Last Patient Last Visit buprenorphine Ph
Slide 26: Financials
ae fe) 2 sO Zz Nz AN —_
Slide 27: Capital Markets Footprint to Align with U.S. Focused Business
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Capital Markets Footprint to Align with U.S. Focused Business Transition from London Stock Exchange (LSE) to Nasdaq rd May 23 th th nd th June 30 July 25 June 2 July 24 Russell U.S. Equity Indexes All Trading on Nasdaq Under Anticipate Inclus
Slide 28: On Track to Achieve FY 2025 Guidance
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 1 On Track to Achieve FY 2025 Guidance – Reaffirmed April 24, 2025 Q1 2025 Results 2025 Financial Guidance Q1 2025 Total Net Revenue (NR) $266m $955 - $1,025m Key Financial Themes 2 SUBLOCADE NR $176m $725 - $765m • Overall Q1 2025 results in
Slide 29: Transition Year: Evolution of the Business in 2025
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 1 Transition Year: Evolution of the Business in 2025 SUBLOCADE Contribution to Expect ~$60m in Non-GAAP 4 Total NR Expected to Increase Operating Expense Savings ~$60m reduction 25% $679m 36% $618M $103m 2 2024 2025E $88m 64% 75% $576m $530m
Slide 30: Generating Significant Cash Flow with Strong Balance Sheet
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Generating Significant Cash Flow with Strong Balance Sheet 1 Growing Non-GAAP EBITDA Key Balance Sheet Items $360m $400m of cash and investments as of Q1 2025 $252m $350m term loan maturing in 2030 $214m with $50m revolving credit facility pr
Slide 31: Transition Year Focus
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Transition Year Focus Deliver 2025 Operating Plan Grow SUBLOCADE Advance the OUD Pipeline Strengthen the Balance Sheet 30
Slide 32: Appendix
Appendix Latosha Regional Head of U.S.Medical Affairs-West, Indian Health Services Medical Lead
Slide 33: Q1 2025 Financial Highlights
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Q1 2025 Financial Highlights 1 OPERATING RESULTS: (REPORTED AND NON-GAAP ) KEY TAKEAWAYS: (VS Q1 2024 UNLESS OTHERWISE INDICATED) $ mil Q1 2025 Q1 2024 Change Total NR decline of 6% (5% at constant FX): • U.S. NR down 8%; lower SUBOXONE Film
Slide 34: Q1 2025 Financial Reconciliations
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 1 Q1 2025 Financial Reconciliations Three Months Ended March 31, Q1 2025 Q1 2024 GAAP selling, general and administrative expenses $ 132 $ 143 Adjustments within SG&A 1 Corporate Initiative Transition 2 0 2 Acquisition-related costs — 2 Less:
Slide 35: FY 2020–2024 Non-GAAP Operating Income Reconciliations
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 FY 2020–2024 Non-GAAP Operating Income Reconciliations Reconciliation of Net Income to Non-GAAP Operating Income ($m) GAAP------------------------------- IFRS------------------- 2024 2023 2022 2021 2020 Net Income 7 ( 126) (42) 205 ( 148) Net
Slide 36: FY 2020–2024 Non-GAAP Operating Expense Reconciliations
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 FY 2020–2024 Non-GAAP Operating Expense Reconciliations Reconciliation of Non-GAAP operating expenses GAAP-------------------------------- IFRS-------------------- 2024 2023 2022 2021 2020 Total Operating Expenses, net 919 1,072 827 451 706 O
Slide 37: FY 2020–2025 Q1 EBITDA Reconciliations
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 FY 2020–2025 Q1 EBTIDA Reconciliations Reconciliation of EBITDA GAAP----------------------------------------------- IFRS--------------------- Q1 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Income 47 7 (126) (42) 205 (148) Add Back: Inter
Slide 38: FY 2024 Leverage Reconciliation
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 FY 2024 Leverage Reconciliation Reconciliation of Leverage Ratio GAAP FY 2024 Total Gross Debt 350 Operating Income 38 Leverage Ratio 9.2 Non-GAAP adjustments in Operations 281 Dep/Amort (excluding ROU Amort) 17 Share-Based Compensation Expen
Slide 39: Global Markets
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Global Markets 1 SUBLOCADE (SUBUTEX®PR (ROW)) SUBOXONE Film Net Revenue by Geography FY 2024 U.S. ●● North America Canada ●● France ●● Italy ●● Germany ●● 85% 2 Denmark, Norway●● Europe & $1,188m Sweden ●● Middle East 15% Finland ●● Switzerla
Slide 40: SUBLOCADE Indication and Important Safety Information
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a
Slide 41: OPVEE Indication and Important Safety Information
I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 OPVEE® (nalmefene) nasal spray INDICATION AND USAGE OPVEE nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 1